title: Polymyxin B protects against hepatic ischemia/reperfusion injury in a rat model of obstructive jaundice.
abstract: This study was conducted in order to investigate the effects of polymyxin B (PMB) against hepatic ischemia/reperfusion (I/R) injury in rats with obstructive jaundice. Thirty-six Wistar rats (eighteen each) with induced hepatic I/R injury by biliary tract ligation and recanalization were assigned to a control group (reperfused with normal saline) and a PMB group (reperfused with PMB). Indicators involving liver function, oxidation resistance, pro-inflammatory state, and anti-apoptosis effect were determined following the instructions. Compared with normal saline, PMB reperfusion resulted in a significant improvement of liver function (increase of glutathione and reduction of aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase), oxidation resistance (decreased malondialdehyde and myeloperoxidase activity), alleviation of pro-inflammatory state (less tumor necrosis factor (TNF)-α, interleukin-1 beta (IL-1β), nuclear factor kappa B (NF-κB) mRNA, and intercellular adhesion molecule (ICAM)-1), and anti-apoptosis effect (more Bcl-2 and less Bax). PMB protects the liver from I/R injury mainly through reducing cellular oncosis and apoptosis and regulating the expression of NF-κB, TNF-α, IL-1β, and ICAM-1.
authors.affiliation: Department of Hepatobiliary and Splenic Surgery, Shengjing Hospital, China Medical University, No. 36 Sanhao Street, Shenyang, Liaoning, 110004, China, daichaoliusjh@126.com.
authors.forename: Feng
authors.initials: F
authors.lastname: Xu
authors.forename: Chao-Liu
authors.initials: CL
authors.lastname: Dai
authors.forename: Song-Lin
authors.initials: SL
authors.lastname: Peng
authors.forename: Yang
authors.initials: Y
authors.lastname: Zhao
authors.forename: Chang-Jun
authors.initials: CJ
authors.lastname: Jia
authors.forename: Yong-Qing
authors.initials: YQ
authors.lastname: Xu
authors.forename: Chuang
authors.initials: C
authors.lastname: Zhao
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D000900:Anti-Bacterial Agents / Q000737:chemistry; D000975:Antioxidants / Q000494:pharmacology; D017209:Apoptosis; D001219:Aspartate Aminotransferases / Q000097:blood; D003404:Creatinine / Q000097:blood; D004195:Disease Models, Animal; D007249:Inflammation / Q000378:metabolism; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism; D041781:Jaundice, Obstructive / Q000188:drug therapy* / Q000517:prevention & control*; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008099:Liver / Q000187:drug effects*; D011112:Polymyxin B / Q000494:pharmacology*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000517:prevention & control*; D051996:Transcription Factor RelA / Q000378:metabolism; D014508:Urea / Q000097:blood; D051028:bcl-2-Associated X Protein / Q000378:metabolism
chemical_list: D000900:Anti-Bacterial Agents; D000975:Antioxidants; C494828:Bax protein, rat; D019253:Proto-Oncogene Proteins c-bcl-2; D012333:RNA, Messenger; C498145:Rela protein, rat; D051996:Transcription Factor RelA; D051028:bcl-2-Associated X Protein; D018799:Intercellular Adhesion Molecule-1; D014508:Urea; D003404:Creatinine; D007770:L-Lactate Dehydrogenase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D011112:Polymyxin B